Sugi Predict

Sugi Predict / Compounds / SCHEMBL7180397

SCHEMBL7180397

SCHEMBL7180397

COCCOc1ccc(PC(=O)c2c(Cl)cccc2OC)c(OCCOC)c1.[LiH]

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 6/20 0.41
▸ ALDH1A1 P00352 3/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ MAPT P10636 8/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39
▸ LMNA P02545 4/20 0.39
▸ SMN1; SMN2 Q16637 3/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ NPC1 O15118 2/20 0.37
▸ RAB9A P51151 2/20 0.37
▸ HPGD P15428 1/20 0.37
▸ CA12 O43570 1/20 0.37
▸ CA1 P00915 1/20 0.37
▸ CA2 P00918 1/20 0.37
▸ CA7 P43166 1/20 0.37
▸ CA9 Q16790 1/20 0.37
▸ CA14 Q9ULX7 1/20 0.37
▸ HCRTR2 O43614 1/20 0.36
▸ POLB P06746 1/20 0.36
▸ MEN1 O00255 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7177487 0.96 L3MBTL1 (0.41) L3MBTL1ALDH1A1KDM4EMAPTTDP1
SCHEMBL7184610 0.93 MAPT (0.41) L3MBTL1ALDH1A1KDM4EMAPTLMNA
SCHEMBL7189884 0.91 ELANE (0.42) L3MBTL1ALDH1A1MAPTTDP1SMN1; SMN2
SCHEMBL7181770 0.91 MEN1 (0.42) L3MBTL1MAPTTDP1SMN1; SMN2MEN1
SCHEMBL7182538 0.91 L3MBTL1 (0.43) L3MBTL1ALDH1A1MAPTTDP1LMNA
SCHEMBL7179737 0.90 KDM4E (0.39) L3MBTL1ALDH1A1KDM4EMAPTTDP1
SCHEMBL7190316 0.90 KDM4E (0.41) L3MBTL1ALDH1A1KDM4EMAPTTDP1
SCHEMBL7180980 0.89 THRA (0.43) L3MBTL1MAPTTDP1MEN1KMT2A
Lithium SCHEMBL7181773 0.89 MEN1 (0.42) L3MBTL1MAPTTDP1SMN1; SMN2MEN1
Lithium SCHEMBL7189888 0.89 ELANE (0.42) L3MBTL1ALDH1A1MAPTTDP1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 — — US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 — — US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 — — US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 L3MBTL1 302/4885ALDH1A1 3416/4885KDM4E 3226/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 L3MBTL1 126/4885ALDH1A1 3984/4885KDM4E 2651/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.